Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
PEN's Cash to Debt is ranked higher than
74% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.26 vs. PEN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PEN' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Equity to Asset 0.85
PEN's Equity to Asset is ranked higher than
88% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. PEN: 0.85 )
Ranked among companies with meaningful Equity to Asset only.
PEN' s Equity to Asset Range Over the Past 10 Years
Min: -0.1  Med: 0.87 Max: 0.88
Current: 0.85
-0.1
0.88
Interest Coverage No Debt
PEN's Interest Coverage is ranked higher than
76% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 71.73 vs. PEN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PEN' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Z-Score: 30.80
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 0.66
PEN's Operating margin (%) is ranked lower than
54% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. PEN: 0.66 )
Ranked among companies with meaningful Operating margin (%) only.
PEN' s Operating margin (%) Range Over the Past 10 Years
Min: -1.27  Med: 2.25 Max: 2.4
Current: 0.66
-1.27
2.4
Net-margin (%) 0.61
PEN's Net-margin (%) is ranked lower than
53% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 2.25 vs. PEN: 0.61 )
Ranked among companies with meaningful Net-margin (%) only.
PEN' s Net-margin (%) Range Over the Past 10 Years
Min: 0.61  Med: 1.79 Max: 4.61
Current: 0.61
0.61
4.61
ROE (%) 0.32
PEN's ROE (%) is ranked lower than
54% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 1.47 vs. PEN: 0.32 )
Ranked among companies with meaningful ROE (%) only.
PEN' s ROE (%) Range Over the Past 10 Years
Min: 0.32  Med: 0.98 Max: 0.98
Current: 0.32
0.32
0.98
ROA (%) 0.54
PEN's ROA (%) is ranked higher than
51% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 0.44 vs. PEN: 0.54 )
Ranked among companies with meaningful ROA (%) only.
PEN' s ROA (%) Range Over the Past 10 Years
Min: 0.54  Med: 2.33 Max: 5.76
Current: 0.54
0.54
5.76
ROC (Joel Greenblatt) (%) 1.86
PEN's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 4.32 vs. PEN: 1.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PEN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3.24  Med: 6.71 Max: 7.26
Current: 1.86
-3.24
7.26
GuruFocus has detected 6 Warning Signs with Penumbra Inc $PEN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

PEN Guru Trades in Q4 2015

PRIMECAP Management 101,300 sh (+1.30%)
Chuck Royce 1,000 sh (unchged)
RS Investment Management Sold Out
Paul Tudor Jones Sold Out
» More
Q1 2016

PEN Guru Trades in Q1 2016

Chuck Royce 1,000 sh (unchged)
PRIMECAP Management 86,800 sh (-14.31%)
» More
Q2 2016

PEN Guru Trades in Q2 2016

Paul Tudor Jones 5,500 sh (New)
Jim Simons 158,600 sh (New)
Chuck Royce 1,000 sh (unchged)
PRIMECAP Management 84,600 sh (-2.53%)
» More
Q3 2016

PEN Guru Trades in Q3 2016

Pioneer Investments 58,492 sh (New)
Steven Cohen 24,700 sh (New)
Jim Simons 186,500 sh (+17.59%)
Chuck Royce 1,000 sh (unchged)
Paul Tudor Jones Sold Out
PRIMECAP Management 79,100 sh (-6.50%)
» More
» Details

Insider Trades

Latest Guru Trades with PEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339999    SIC: 3841
Compare:OTCPK:NHNKY, NAS:LIVN, NAS:ZLTQ, NYSE:NVRO, NAS:WMGI, NYSE:GMED, NAS:INGN, OTCPK:IOBCF, NAS:BABY, NAS:CNMD, NAS:SPNC, NAS:CYNO, NAS:IART, NAS:MDXG, NAS:VASC, NYSE:ITGR, NAS:KTWO, NAS:CSII, NAS:MASI, OTCPK:EKTAY » details
Traded in other countries:0P8.Germany,
Penumbra Inc designs, develops, manufactures and markets medical devices. The products of the company address ischemic stroke, hemorrhagic stroke and vascular conditions that can be treated through thrombectomy and embolization procedures.

Penumbra Inc was incorporated in 2004 as a Delaware corporation under the name Penumbra. It is an interventional therapies company that designs, develops, manufactures and markets medical devices. The products of the company address ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. The Company sells its products to hospitals through its salesforce, as well as through distributors. It sells its products through direct sales organization in the United States, Europe, Canada and Australia. Its products include Penumbra System, ACE, Penumbra Coil 400, Penumbra SMART COIL, LIBERTY Stent, Apollo System, Ruby Coil and Indigo System. The Company competes with manufacturers and distributors of neurovascular and peripheral vascular medical devices. Its competitors are Boston Scientific, Johnson & Johnson, Medtronic, Stryker and Terumo. Its products are medical devices subject to extensive and ongoing regulation by the FDA under the Federal Food, Drug, and Cosmetic Act (FD&C Act), and its implementing regulations, as well as other federal and state regulatory bodies in the United States and comparable authorities in other countries under other statutes and regulations.

Ratios

vs
industry
vs
history
P/E(ttm) 1478.00
PEN's P/E(ttm) is ranked lower than
99% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 26.07 vs. PEN: 1478.00 )
Ranked among companies with meaningful P/E(ttm) only.
PEN' s P/E(ttm) Range Over the Past 10 Years
Min: 18.68  Med: 504.08 Max: 1546.4
Current: 1478
18.68
1546.4
Forward P/E 500.00
PEN's Forward P/E is ranked lower than
98% of the 56 Companies
in the Global Medical Devices industry.

( Industry Median: 24.39 vs. PEN: 500.00 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 1478.00
PEN's PE(NRI) is ranked lower than
99% of the 173 Companies
in the Global Medical Devices industry.

( Industry Median: 25.71 vs. PEN: 1478.00 )
Ranked among companies with meaningful PE(NRI) only.
PEN' s PE(NRI) Range Over the Past 10 Years
Min: 18.7  Med: 504.08 Max: 1546.4
Current: 1478
18.7
1546.4
P/B 9.19
PEN's P/B is ranked lower than
87% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 3.17 vs. PEN: 9.19 )
Ranked among companies with meaningful P/B only.
PEN' s P/B Range Over the Past 10 Years
Min: 4.83  Med: 7.07 Max: 9.64
Current: 9.19
4.83
9.64
P/S 7.54
PEN's P/S is ranked lower than
80% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 3.08 vs. PEN: 7.54 )
Ranked among companies with meaningful P/S only.
PEN' s P/S Range Over the Past 10 Years
Min: 3.57  Med: 4.68 Max: 7.89
Current: 7.54
3.57
7.89
EV-to-EBIT 1199.91
PEN's EV-to-EBIT is ranked lower than
99% of the 166 Companies
in the Global Medical Devices industry.

( Industry Median: 21.95 vs. PEN: 1199.91 )
Ranked among companies with meaningful EV-to-EBIT only.
PEN' s EV-to-EBIT Range Over the Past 10 Years
Min: 81.4  Med: 442.4 Max: 1371.4
Current: 1199.91
81.4
1371.4
EV-to-EBITDA 491.99
PEN's EV-to-EBITDA is ranked lower than
99% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 16.63 vs. PEN: 491.99 )
Ranked among companies with meaningful EV-to-EBITDA only.
PEN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 52.7  Med: 312.3 Max: 562.3
Current: 491.99
52.7
562.3
Current Ratio 7.16
PEN's Current Ratio is ranked higher than
88% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. PEN: 7.16 )
Ranked among companies with meaningful Current Ratio only.
PEN' s Current Ratio Range Over the Past 10 Years
Min: 4.4  Med: 7.46 Max: 8.81
Current: 7.16
4.4
8.81
Quick Ratio 5.28
PEN's Quick Ratio is ranked higher than
85% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. PEN: 5.28 )
Ranked among companies with meaningful Quick Ratio only.
PEN' s Quick Ratio Range Over the Past 10 Years
Min: 2.75  Med: 5.51 Max: 7.03
Current: 5.28
2.75
7.03
Days Inventory 271.53
PEN's Days Inventory is ranked lower than
80% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 131.45 vs. PEN: 271.53 )
Ranked among companies with meaningful Days Inventory only.
PEN' s Days Inventory Range Over the Past 10 Years
Min: 258.85  Med: 265.39 Max: 318.98
Current: 271.53
258.85
318.98
Days Sales Outstanding 54.66
PEN's Days Sales Outstanding is ranked higher than
69% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 67.65 vs. PEN: 54.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
PEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.71  Med: 55 Max: 57.75
Current: 54.66
53.71
57.75
Days Payable 15.59
PEN's Days Payable is ranked lower than
91% of the 253 Companies
in the Global Medical Devices industry.

( Industry Median: 56.36 vs. PEN: 15.59 )
Ranked among companies with meaningful Days Payable only.
PEN' s Days Payable Range Over the Past 10 Years
Min: 15.1  Med: 15.46 Max: 20.09
Current: 15.59
15.1
20.09

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Net Cash 23.76
PEN's Price/Net Cash is ranked lower than
61% of the 101 Companies
in the Global Medical Devices industry.

( Industry Median: 17.13 vs. PEN: 23.76 )
Ranked among companies with meaningful Price/Net Cash only.
PEN' s Price/Net Cash Range Over the Past 10 Years
Min: 9.33  Med: 13.69 Max: 24.43
Current: 23.76
9.33
24.43
Price/Net Current Asset Value 10.45
PEN's Price/Net Current Asset Value is ranked lower than
65% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 6.60 vs. PEN: 10.45 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PEN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 5.48  Med: 7.56 Max: 10.75
Current: 10.45
5.48
10.75
Price/Tangible Book 9.21
PEN's Price/Tangible Book is ranked lower than
76% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 4.35 vs. PEN: 9.21 )
Ranked among companies with meaningful Price/Tangible Book only.
PEN' s Price/Tangible Book Range Over the Past 10 Years
Min: 5.23  Med: 6.92 Max: 9.47
Current: 9.21
5.23
9.47
Price/Median PS Value 1.61
PEN's Price/Median PS Value is ranked lower than
82% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.01 vs. PEN: 1.61 )
Ranked among companies with meaningful Price/Median PS Value only.
PEN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.82  Med: 0.98 Max: 1.66
Current: 1.61
0.82
1.66
Price/Graham Number 24.63
PEN's Price/Graham Number is ranked lower than
98% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. PEN: 24.63 )
Ranked among companies with meaningful Price/Graham Number only.
PEN' s Price/Graham Number Range Over the Past 10 Years
Min: 2.17  Med: 12.82 Max: 25.33
Current: 24.63
2.17
25.33
Earnings Yield (Greenblatt) (%) 0.10
PEN's Earnings Yield (Greenblatt) (%) is ranked lower than
53% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.00 vs. PEN: 0.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PEN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 0.2 Max: 1.2
Current: 0.1
0.1
1.2

More Statistics

Revenue (TTM) (Mil) $244.6
EPS (TTM) $ 0.05
Short Percentage of Float8.40%
52-Week Range $40.23 - 79.49
Shares Outstanding (Mil)31.64

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 258 314 370 435
EPS ($) -0.09 0.15 0.43 0.89
EPS w/o NRI ($) -0.09 0.15 0.43 0.89
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for PEN

Headlines

Articles On GuruFocus.com

More From Other Websites
Zacks.com featured highlights: Ollie's Bargain Outlet Holdings, Premier, Penumbra, DigitalGlobe and... Jan 17 2017
Medidata Solutions Clinical Cloud Gets Picked by Celgene Jan 17 2017
Pacific Biosciences (PACB) to Sell 10 PacBio Sequel Systems Jan 17 2017
VWR Buys SEASTAR CHEMICALS to Boost Americas Division Jan 17 2017
Akers Biosciences (AKER) Closes Offering of 1.7M Shares Jan 16 2017
Intuitive Surgical (ISRG) Expects Strong Revenues in Q4 Jan 13 2017
Henry Schein Hurt by Higher Costs, Lacks Growth Drivers Jan 12 2017
Illumina and Bio-Rad Unveil Single-Cell Sequencing Solution Jan 12 2017
NuVasive at 52-Week High on Preliminary Results, MHLW Nod Jan 12 2017
Luminex Projects Strong Q4 Revenues, Issues 2017 Guidance Jan 11 2017
DexCom Looking Forward to Strong Revenues in Q4 and 2016 Jan 11 2017
Teleflex Launches LMA Gastro Airway, FDA Okays Arrow VPS Jan 11 2017
PerkinElmer (PKI) to Acquire India-Based Tulip Diagnostics Jan 10 2017
Allscripts (MDRX) Q4 Bookings Likely to Hit Record Levels Jan 10 2017
Air Methods (AIRM): Winter Hits December Passenger Count Jan 09 2017
AngioDynamics (ANGO) Beats Q2 Earnings, Lifts 2017 View Jan 09 2017
Cerner Extends HNM Partnership with University of Missouri Jan 06 2017
Alere Forensic Toxicology Division Gets ABFT Accreditation Jan 06 2017
Luminex (LMNX) Gets FDA Clearance for ARIES GBS Assay Jan 05 2017
Penumbra, Inc. breached its 50 day moving average in a Bullish Manner : PEN-US : January 5, 2017 Jan 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)